BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 22904352)

  • 21. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
    Stuchlova Horynova M; Vrablikova A; Stewart TJ; Takahashi K; Czernekova L; Yamada K; Suzuki H; Julian BA; Renfrow MB; Novak J; Raska M
    Nephrol Dial Transplant; 2015 Feb; 30(2):234-8. PubMed ID: 25281698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.
    Moldoveanu Z; Wyatt RJ; Lee JY; Tomana M; Julian BA; Mestecky J; Huang WQ; Anreddy SR; Hall S; Hastings MC; Lau KK; Cook WJ; Novak J
    Kidney Int; 2007 Jun; 71(11):1148-54. PubMed ID: 17342176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.
    Xu LX; Zhao MH
    Kidney Int; 2005 Jul; 68(1):167-72. PubMed ID: 15954905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
    Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
    PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura.
    Lau KK; Wyatt RJ; Moldoveanu Z; Tomana M; Julian BA; Hogg RJ; Lee JY; Huang WQ; Mestecky J; Novak J
    Pediatr Nephrol; 2007 Dec; 22(12):2067-72. PubMed ID: 17943324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
    Suzuki H; Fan R; Zhang Z; Brown R; Hall S; Julian BA; Chatham WW; Suzuki Y; Wyatt RJ; Moldoveanu Z; Lee JY; Robinson J; Tomana M; Tomino Y; Mestecky J; Novak J
    J Clin Invest; 2009 Jun; 119(6):1668-77. PubMed ID: 19478457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.
    Liu Y; Liu X; Jia J; Zheng J; Yan T
    J Transl Med; 2019 Sep; 17(1):320. PubMed ID: 31547815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.
    Wang M; Lv J; Chen P; Yu G; Shi S; Liu L; Zhou X; Xu D; Zhao M; Zhang H
    Nephrol Dial Transplant; 2021 Jan; 36(2):288-294. PubMed ID: 31603230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
    Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
    Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
    Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
    BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
    Zachova K; Jemelkova J; Kosztyu P; Ohyama Y; Takahashi K; Zadrazil J; Orsag J; Matousovic K; Galuszkova D; Petejova N; Mestecky J; Raska M
    J Am Soc Nephrol; 2022 May; 33(5):908-917. PubMed ID: 35115327
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Liu XZ; Zhang YM; Jia NY; Zhang H
    Ren Fail; 2020 Nov; 42(1):539-546. PubMed ID: 32524871
    [No Abstract]   [Full Text] [Related]  

  • 33. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
    Martín-Penagos L; Fernández-Fresnedo G; Benito-Hernández A; Mazón J; de Cos M; Oviedo MV; San Segundo D; López-Hoyos M; Gómez-Román J; Ruiz JC; Rodrigo E
    Nefrologia (Engl Ed); 2021; 41(3):311-320. PubMed ID: 33741175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
    Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
    Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.
    Yasutake J; Suzuki Y; Suzuki H; Hiura N; Yanagawa H; Makita Y; Kaneko E; Tomino Y
    Nephrol Dial Transplant; 2015 Aug; 30(8):1315-21. PubMed ID: 26109484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
    Suzuki H; Moldoveanu Z; Hall S; Brown R; Julian BA; Wyatt RJ; Tomana M; Tomino Y; Novak J; Mestecky J
    Contrib Nephrol; 2007; 157():129-33. PubMed ID: 17495450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.
    Moldoveanu Z; Suzuki H; Reily C; Satake K; Novak L; Xu N; Huang ZQ; Knoppova B; Khan A; Hall S; Yanagawa H; Brown R; Winstead CJ; O'Quinn DB; Weinmann A; Gharavi AG; Kiryluk K; Julian BA; Weaver CT; Suzuki Y; Novak J
    J Autoimmun; 2021 Mar; 118():102593. PubMed ID: 33508637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
    Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
    BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal glucose metabolism and galactose-deficient immunoglobulin A1 (IgA1) synthesis: a possible mechanism of IgA nephropathy.
    Lai L; Liu T; Yan M; Shang D; Qian J; Hao C; Xue J
    Discov Med; 2019 Jul; 28(151):39-45. PubMed ID: 31465724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers in IgA nephropathy: relationship to pathogenetic hits.
    Hastings MC; Moldoveanu Z; Suzuki H; Berthoux F; Julian BA; Sanders JT; Renfrow MB; Novak J; Wyatt RJ
    Expert Opin Med Diagn; 2013 Nov; 7(6):615-27. PubMed ID: 24175678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.